Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: trastuzumab|DRUG: erlotinib hydrochloride
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Genentech, Inc.